Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behcet's Uveitis: A Small Case Series

Celiker H., Kazokoglu H., Direskeneli H.

OCULAR IMMUNOLOGY AND INFLAMMATION, vol.27, no.1, pp.15-22, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1080/09273948.2017.1332768
  • Page Numbers: pp.15-22
  • Keywords: Behcet's uveitis, interferon therapy, pegylated interferon alpha-2b, treatment, uveitis, ALPHA-2A THERAPY, HEPATITIS-C, PHARMACOKINETICS, COMPLICATIONS, ATTACHMENT, DISEASE, SAFETY


Purpose: To assess the long-term efficacy and safety of pegylated interferon alpha-2b (peg-IFN-alpha-2b) for severe uveitis associated with Behcet's disease. Methods: Peg-IFN-alpha-2b was administrated at an initial dosage of 0,5-1,5 mu g/kg/week. If any complications were observed, the dosage was tapered. Ocular examinations, systemic findings, and treatment compliance of the patients were evaluated. Results: Control of ocular inflammation was achieved in all patients (n = 4). The average increase in visual acuity after drug administration of 0,425 +/- 0,125 logMAR was not statistically significant (Wilcoxon Test, p = 0,066) due to small number of cases. Any side-effects with laboratory abnormalities returned to baseline levels with reduction of the doses. Due to less frequent injections, increased satisfaction of the patients was noted. Conclusions: This series highlights the peg-IFN-alpha-2b administration in Behcet's uveitis. Peg-IFN-alpha-2b has a potential long-term therapeutic effect for the treatment of severe uveitis. Efficacy with a reduced number of injections improved the quality of Behcet patients' lives.